102 related articles for article (PubMed ID: 24921414)
1. Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients.
Kurzawski M; Malinowski D; Dziewanowski K; Droździk M
Pharmacogenet Genomics; 2014 Aug; 24(8):397-400. PubMed ID: 24921414
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
Elens L; Sombogaard F; Hesselink DA; van Schaik RH; van Gelder T
Pharmacogenet Genomics; 2013 Dec; 23(12):649-57. PubMed ID: 24113216
[TBL] [Abstract][Full Text] [Related]
3. Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients.
Si S; Wang Z; Yang H; Han Z; Tao J; Chen H; Wang K; Guo M; Tan R; Wei JF; Gu M
Pharmacogenomics J; 2019 Feb; 19(1):42-52. PubMed ID: 30323313
[TBL] [Abstract][Full Text] [Related]
4. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
5. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.
Everton JBF; Patrício FJB; Faria MS; Ferreira TCA; Romao EA; Silva GEB; Magalhães M
Eur J Clin Pharmacol; 2021 Jun; 77(6):879-886. PubMed ID: 33398393
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
Lancia P; Adam de Beaumais T; Elie V; Garaix F; Fila M; Nobili F; Ranchin B; Testevuide P; Ulinski T; Zhao W; Deschênes G; Jacqz-Aigrain E
Pediatr Nephrol; 2018 Jun; 33(6):1045-1055. PubMed ID: 29399716
[TBL] [Abstract][Full Text] [Related]
8. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.
Woillard JB; Kamar N; Coste S; Rostaing L; Marquet P; Picard N
Clin Chem; 2013 Dec; 59(12):1761-9. PubMed ID: 23974086
[TBL] [Abstract][Full Text] [Related]
10. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism.
Yao B; Chen X; Shen FX; Xu W; Dong TT; Chen LZ; Weng JP
Transplant Proc; 2013; 45(1):194-6. PubMed ID: 23375298
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
Numakura K; Satoh S; Tsuchiya N; Horikawa Y; Inoue T; Kakinuma H; Togashi H; Matsuura S; Tada H; Suzuki T; Habuchi T
Transplant Proc; 2005 May; 37(4):1865-7. PubMed ID: 15919487
[TBL] [Abstract][Full Text] [Related]
12. KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients.
Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Ruiz-Ortega M; Alvarez V;
Clin Transplant; 2011; 25(3):E284-91. PubMed ID: 21355884
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.
Shi D; Xie T; Deng J; Niu P; Wu W
Eur J Clin Pharmacol; 2018 Jun; 74(6):723-729. PubMed ID: 29546446
[TBL] [Abstract][Full Text] [Related]
14. Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers.
Fougeray S; Loriot MA; Nicaud V; Legendre C; Thervet E; Pallet N
Transplant Proc; 2011 Nov; 43(9):3418-22. PubMed ID: 22099811
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A4 and PPARA polymorphism on concentration-to-dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients.
Azam F; Khan M; Shaheen A; Bhatti AH
Pak J Med Sci; 2022; 38(7):1893-1898. PubMed ID: 36246675
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients.
Chen Y; Sampaio MS; Yang JW; Min D; Hutchinson IV
Transplantation; 2012 Feb; 93(3):325-30. PubMed ID: 22234350
[TBL] [Abstract][Full Text] [Related]
20. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients.
Ferraresso M; Tirelli A; Ghio L; Grillo P; Martina V; Torresani E; Edefonti A
Pediatr Transplant; 2007 May; 11(3):296-300. PubMed ID: 17430486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
